CDW7 Making the Transition to Translational Research

Program: Career Development Workshops
Translational Session
Sunday, April 3, 2016: 7:00 PM-9:00 PM
Harbor BR1 (The Westin)

Registration is required for this session:
$30 (Food Provided)


Joanna Elizabeth Burdette, Ph.D., University of Illinois at Chicago, Chicago, IL

Dr. Joanna E. Burdette joined the faculty at the University of Illinois at Chicago in the Department of Medicinal Chemistry and Pharmacognosy in 2007. She earned her B.S. from Emory University in Biology in 1999. She completed a Ph.D. at UIC in 2003 studying botanical dietary supplements for the alleviation of menopausal symptoms. She was a postdoctoral fellow at Northwestern under the direction of Dr. Teresa K. Woodruff until 2007. Her postdoctoral research centered on ovulation and ovarian cancers. Since 2007, she has worked to develop three-dimensional models of normal ovarian surface cells and oviductal epithelium to determine the source and early events responsible for ovarian cancer formation. In collaboration with Dr. Thomas Meade, she is characterizing targeted contrast agent that accumulate and mark steroid-receptor expressing cells. These progesterone contrast agents might ultimately be used to diagnose hormone dependent cancers in vivo. Lastly, the lab is identifying novel sources of anti-cancer molecules from marine derived sources.

Margaret E Wierman, MD, University of Colorado School of Medicine and Research Service VAMC, Aurora,

Margaret E. Wierman is Professor in Medicine, Physiology and Biophysics at the University of Colorado School of Medicine and Chief of Endocrinology at the Denver VA. She is the past Vice President Clinical Scientist at the Endocrine Society and President of Women in Endocrinology. She has served on many Endocrine Society committees including chairing the Annual Meeting Steering Committee and the Meetings and Educational Programs Committee, Councilor-at-Large and member of Finance, Nominating and Awards Committees and chaired the Endocrine Society Task force on the role of Androgens in Women. She has also served on and chaired multiple NIH Study Sections including the Population Research Subcommittee, the Specialized Programs in Reproduction and the Integrative Clinical Endocrinology and Reproductive Section and served on the Endocrine and Metabolic Drugs panel for the FDA. She received the 2009 Sydney H. Ingbar Distinguished Service Award, given in recognition of distinguished service in the field of Endocrinology. Current research includes clinical research on the role of neuroendocrine dysfunction after traumatic brain injury and basic and translation research on GnRH neuron development and endocrine neoplasia. Clinically she is interested broadly in hormonal disorders of women and men and pituitary and adrenal tumors.

Aditi Bhargava, PHD, UCSF, San Francisco, CA

Dr. Bhargava, Associate Professor in the Department of ObGyn, serves as a mentor for postdoctoral fellows, residents, junior faculty, and summer students. Her research focuses on the role of neuropeptides and their receptors in inflammation, stress and pain. The general objective is to understand the molecular and cellular mechanisms by which corticotropin-releasing factor (CRF) family of neuropeptides and their G-protein coupled receptors regulate stress-induced cellular signaling. An estimated 57 million people in the US alone suffer from stress-related disorders. Twice as many women as men suffer from these conditions, which include autoimmune disorders, anxiety and depression. The same disease has sex-specific outcomes, but the cellular basis for these sex differences is not understood. The CRF system consists of the neuropeptides CRF and Urocortins 1-3 (Ucn1-3), and two G protein-coupled receptors (GPCRs), CRF1 and CRF2.The CRF family coordinates stress responses by acting both as a hormone to initiate the hypothalamic-pituitary-adrenal axis and as a neuromodulator in the brain and the periphery. However, the precise role of the CRF system in mediating sex-specific cellular signaling and stress responses has yet to be elucidated. With acute or prolonged stress, CRF responses in the brain are more likely to shift into a dysregulated state in females. Despite the preponderance of stress-related diseases in females, use of female animal subjects is perpetually lacking sex-specific molecular pathogenesis in disease responses remain vastly understudied. The work in my lab is characterized by its use of male and female animals and side-by-side comparison of cellular components that determine sex-specific responses. We use a combination of technically challenging cell biology approaches such as mass spectrometry, electron microscopy, and deep sequencing to identify and localize cellular interacting partners in tissue samples obtained from in vivo animal models of human disease and patient tissues.

Daniel J Drucker, MD, Mt Sinai Hospital, Toronto, Canada

Dr. Drucker is currently Professor of Medicine at the University of Toronto. He holds a Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His laboratory is based in the Lunenfeld Tanenbaum Research Institute at Mt. Sinai Hospital in Toronto and studies the molecular biology and physiology of the glucagon-like peptides.

Louis V DePaolo, NICHD/NIH, Bethesda, MD

Dr. Louis DePaolo is Chief of the Fertility and Infertility Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). In this role, Dr. DePaolo provides oversight leadership of the Institute’s portfolio of grants dealing with basic, translational, and clinical studies in male and female fertility regulation. The branch is the single largest Federal funding source for research and research training programs in reproduction and infertility providing support for nearly 300 grant awards totaling approximately 90 million dollars. Dr. DePaolo received his doctorate in Physiology from the University of Maryland School of Medicine, and held faculty appointments at the University of Texas Health Science Center in San Antonio (tenured), and the Salk and Whittier Institutes in California. During this period, Dr. DePaolo received research, research training, and career development support from the National Institutes of Health leading to more than 60 publications on the neuroendocrine control of reproduction. Since joining the NICHD in 1994, Dr. DePaolo has established the Reproductive Neuroendocrinology and Ovarian Biology Programs, as well as the Specialized Cooperative Centers Program in Reproduction and Infertility Research (SCCPIR) and the Contraception and Infertility Research Loan Repayment Program (CIR-LRP), which became the first NIH extramural loan forgiveness program. Recently, Dr. DePaolo initiated an interagency Dual-Purpose, Dual-Benefit (DP/DB) Program with the United States Department of Agriculture to support research addressing biomedicine and agriculture using large animal models. Internationally, he has established a Visiting Scientist Training Award (VSTA) Program with the South Korean government to allow Korean fellows and early career faculty members to receive training in reproductive epidemiology and population surveillance at the NICHD or the Centers for Disease Control and Prevention. Under his leadership, branch staff have initiated programs aimed at increasing workforce diversity in the reproductive sciences and enhancing community outreach and education.

DJD: Speaker, Astra Zeneca, Advisory Group Member, Novo Nordisk, Advisory Group Member, Merck & Co.. Nothing to Disclose: JEB, MEW, AB, LVD

After this session, attendees will be able to:

  • Understand the key differences between basic and translational research.
  • Understand what questions are important to ask when developing a translational research plan
  • Understand the challenges and mechanisms to facilitate team science in the translational arena
  • Learn from anecdotal accounts of investigators who are funded and published in translational research
  • Identify opportunities to pursue disease- or patient-oriented and pre-clinical trial research.